Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.33 | 2.31% | 0.03 |
MRNS closed up 2.31 percent on Friday, May 17, 2024, on 54 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 22
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 2.31% | |
| Narrow Range Bar | Range Contraction | 2.31% | |
| Down 3 Days in a Row | Weakness | 2.31% | |
| Oversold Stochastic | Weakness | 2.31% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -0.75% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 2 days ago |
| Up 5% | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Up 3% | 2 days ago |
| Up 2% | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/22/2024
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Seizure Ketones Sedatives Fragile X Syndrome Pregnanes Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.26 |
| 52 Week Low | 1.11 |
| Average Volume | 2,411,590 |
| 200-Day Moving Average | 7.43 |
| 50-Day Moving Average | 5.07 |
| 20-Day Moving Average | 1.41 |
| 10-Day Moving Average | 1.38 |
| Average True Range | 0.27 |
| RSI (14) | 19.35 |
| ADX | 63.5 |
| +DI | 11.03 |
| -DI | 41.15 |
| Chandelier Exit (Long, 3 ATRs) | 0.95 |
| Chandelier Exit (Short, 3 ATRs) | 1.99 |
| Upper Bollinger Bands | 1.55 |
| Lower Bollinger Band | 1.28 |
| Percent B (%b) | 0.19 |
| BandWidth | 19.26 |
| MACD Line | -0.98 |
| MACD Signal Line | -1.24 |
| MACD Histogram | 0.2577 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.45 | ||||
| Resistance 3 (R3) | 1.45 | 1.42 | 1.43 | ||
| Resistance 2 (R2) | 1.42 | 1.39 | 1.42 | 1.42 | |
| Resistance 1 (R1) | 1.37 | 1.37 | 1.40 | 1.37 | 1.42 |
| Pivot Point | 1.34 | 1.34 | 1.35 | 1.34 | 1.34 |
| Support 1 (S1) | 1.29 | 1.31 | 1.32 | 1.29 | 1.24 |
| Support 2 (S2) | 1.26 | 1.29 | 1.26 | 1.24 | |
| Support 3 (S3) | 1.21 | 1.26 | 1.23 | ||
| Support 4 (S4) | 1.21 |
